Www2.eucerin.at
Weitere Studien mit Eucerin® Trockene Haut Präparaten
Diese Studien können Sie gerne anfordern bei: Beiersdorf AG, Dermo cosmetics & Health care,
Bf 67, Unnastraße 8, 05 Hamburg
10 % urea lotion – concomitant treatment of
extremely
la nouvelle rèsponse aux problèmes des
peaux sèches.
Wirksamkeit und Verträglichkeit von eucerin® repair salbe
Fettstoffwechselstörung der Haut.
dry skin in the dermatologists office.
10 % urea bei
xerotischer Altershaut. ergebnisse einer
réalités thérapeutiques en dermato-Vénérologie 2004, 133 (supplement 1): 3–7
Vehikel-kontrollierten klinischen doppelblindstudie.
poster presentation, 16th eadV congress Vienna 2007
schölermann, a., Bohnsack, k., stephan, k., Banke-Bochita, J., herrmann, W.m.,
moist skin care can diminish
acute radiation-induced
rippke, f., z. hautkr. 1999, 74 (10): 557–562
the combination prostaglandin e and gamma-linolenic
skin toxicity.
itch relief by topical application of an emulsion spray
acid demonstrates synergistic/additive enhanced anti-
(eucerin® akutspray) in patients with
chronic dry skin
momm, f., Weißenberger, c., Bartelt, s., henke, m.,
efficacy of urea therapy in children with
ichthyosis.
strahlenther. onkol. 2003, 179: 708–712
condition.
küster, W., Bohnsack, k., rippke, f., upmeyer, h.-J., groll, s., traupe, h.,
tausch, i., hughes, B., maas-irslinger, r., melnik, B., plewig, g., rippke, f.,
gaßmüller, J., J. invest. dermatol. 1995, 104 (4): 660
a. schölermann, u. gieler, f. rippke, poster presentation, 16th eadV congress Vienna 2007
eucerin
® repair fußcreme 10 % urea: ergebnisse zweier
klinischer studien bei
atopischer und diabetischer
efficacy and safety of eucerin® repair lotion 10 % urea
internationale, multizentrische prüfung der Wirksamkeit
Xerodermie der Füße.
und Verträglichkeit der externen therapie
chronischer
Benficial effects of an new lip balm in patients with
in the treatment of symptoms of
aged skin.
Ekzeme mit einem 10 %igen harnstoffpräparat.
cheilitis sicca, lip lick eczema and dry lips due to
schölermann, a., filbry, a., rippke, f.,
schölermann, a., Banke-Bochita, J., Bohnsack, k., rippke, f., herrmann, W.m.,
J. dermatol. treat. 1998, 9 (3): 175–179
Vilaplana, J., mohr, p., Weichenthal, m., leonhartsberger,h., Weidenhammer, W.,
Isotretinoin therapy.
gerlach, k., schmidt, J. B., ring, J., mascaro, raab, W.,
u. scherdin, t.c. roos, g. popp, a. schölermann, uc. schröder, f. rippke,
poster presentation, 15th eadV congress rhodes 2006
modulation of
atopy patch test reactions by topical
harnstoff – ein wichtiger Wirkstoff in der dermatologie.
treatment of human skin with a fatty acid-rich emollient.
tausch, i., hughes-formella, B., schölermann, a., rippke, f.,
efficacy and tolerability of a hand cream containing
Billmann-eberwein, c., rippke, f., ruzicka, t., krutmann, J.,
5 % urea and sodium lactat in patients with
dry skin
protective and regenerative effects of gamolenic acid on
and associated dermatoses.
atopic skin.
a. schölermann, k. Bohnsack, a. filbry, r.l. rizer, t.m. Weber, poster presentation, 15th eadV congress rhodes 2006
therapie der
trockenen, juckenden Kopfhaut.
Wulfhorst, B., rippke, f., schwanitz, h. J., austral. J. dermatol. 1997, 38 (suppl. 2): 241
küster, W., schölermann, a., rippke, f., derm 2001, 7: 257–259
Beneficial effects of a medical hand care system in
efficacy of eucerin® 10% urea cream and aquadrate creme
different skin conditions and in hand eczema.
effect of topically applied evening primrose oil on
in the treatment of
xeroderma.
Bohnsack, k., scherdin, u., filbry, a., schölermann, a., rippke, f., J. eur. acad. derm. Venereol. 2004, 18 (suppl. 2): 221
epidermal barrier function in
atopic dermatitis as a
tausch, i., Bohnsack, k., schölermann, a., rippke, f., gaßmül er, J., austral. J. dermatol. 1997, 38 (suppl. 2): 102
stratum corneum ph in
atopic dermatitis – impact on skin
gehring, W., Bopp, r., rippke, f., gloor, m., arzneim.-forsch./drug res. 1999, 49 (ii): 635–642
10 % urea creme for
atopic dermatitis: a clinical and
barrier function and colonization with staphylococcus
fatty acid uptake by cultured human keratinocytes grown
pigatto, p. d., Bigardi, a. s., cannistraci, c., picardo, m., J. dermatol. treat. 1996,
rippke, f., schreiner, V., doering, t., maibach, h. i.,
am. J. clin. dermatol. 2004, 5: 217–223
in essential fatty acid- (efa-) deficient or efa-supplemented medium.
schürer, n. Y., rippke, f., flesche, c., Vogelsang, k., schliep, V., ruzicka, t., arch. dermatol. res. 1999, 291: 47–53
Source: http://www2.eucerin.at/media/pdf/weitere_studien.pdf
LOPRESSOR - metoprolol tartrate tablet LOPRESSOR - metoprolol tartrate injection, solution Novartis Pharmaceuticals Corporation metoprolol tartrate tablets, USP metoprolol tartrate injection, USP Rx only Prescribing Information DESCRIPTION Lopressor, metoprolol tartrate USP, is a selective beta1-adrenoreceptor blocking agent, available as 50- and 100-mg tablets for oral administration
ORIGINAL RESEARCH Bupropion and Restless Legs Syndrome:A Randomized Controlled Trial Max Bayard, MD, Beth Bailey, PhD, Deep Acharya, MD, Farhana Ambreen, MD,Sonia Duggal, MD, Taran Kaur, MD, Zia Ur Rahman, MD, Kim Roller, MD,and Fred Tudiver, MD Introduction: Restless legs syndrome (RLS) is a common neurological disorder affecting 10% of the population. Most antidepressants exacerbate sy